Certuity LLC Has $347,000 Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Certuity LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 26.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,885 shares of the medical equipment provider’s stock after buying an additional 809 shares during the quarter. Certuity LLC’s holdings in Boston Scientific were worth $347,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of the company. Values First Advisors Inc. acquired a new position in Boston Scientific during the 3rd quarter worth $28,000. Dunhill Financial LLC lifted its position in shares of Boston Scientific by 86.4% during the 3rd quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 152 shares during the last quarter. Global Wealth Strategies & Associates boosted its stake in Boston Scientific by 423.7% during the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 250 shares during the period. West Oak Capital LLC acquired a new stake in Boston Scientific in the 4th quarter valued at approximately $29,000. Finally, E Fund Management Hong Kong Co. Ltd. bought a new position in Boston Scientific in the 3rd quarter worth approximately $30,000. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

BSX has been the topic of several research analyst reports. Raymond James raised their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a “strong-buy” rating in a research note on Thursday, February 6th. Citigroup boosted their price objective on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. TD Cowen increased their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Thursday, December 12th. Bank of America boosted their price target on Boston Scientific from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Finally, Canaccord Genuity Group raised their price objective on Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and an average target price of $107.39.

Insiders Place Their Bets

In related news, EVP John Bradley Sorenson sold 4,119 shares of Boston Scientific stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig sold 12,000 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $105.48, for a total transaction of $1,265,760.00. Following the completion of the transaction, the director now directly owns 24,398 shares in the company, valued at $2,573,501.04. This trade represents a 32.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 65,830 shares of company stock valued at $6,415,729 in the last 90 days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

NYSE:BSX opened at $105.80 on Thursday. The stock has a market capitalization of $155.93 billion, a P/E ratio of 84.64, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 1 year low of $64.54 and a 1 year high of $107.17. The firm has a 50 day moving average of $95.50 and a 200-day moving average of $87.72. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.